Peters, S.; Wirkert, E.; Kuespert, S.; Heydn, R.; Johannesen, S.; Friedrich, A.; Mailänder, S.; Korte, S.; Mecklenburg, L.; Aigner, L.;
et al. Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics 2022, 14, 200.
https://doi.org/10.3390/pharmaceutics14010200
AMA Style
Peters S, Wirkert E, Kuespert S, Heydn R, Johannesen S, Friedrich A, Mailänder S, Korte S, Mecklenburg L, Aigner L,
et al. Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics. 2022; 14(1):200.
https://doi.org/10.3390/pharmaceutics14010200
Chicago/Turabian Style
Peters, Sebastian, Eva Wirkert, Sabrina Kuespert, Rosmarie Heydn, Siw Johannesen, Anita Friedrich, Susanne Mailänder, Sven Korte, Lars Mecklenburg, Ludwig Aigner,
and et al. 2022. "Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders" Pharmaceutics 14, no. 1: 200.
https://doi.org/10.3390/pharmaceutics14010200
APA Style
Peters, S., Wirkert, E., Kuespert, S., Heydn, R., Johannesen, S., Friedrich, A., Mailänder, S., Korte, S., Mecklenburg, L., Aigner, L., Bruun, T.-H., & Bogdahn, U.
(2022). Safe and Effective Cynomolgus Monkey GLP—Tox Study with Repetitive Intrathecal Application of a TGFBR2 Targeting LNA-Gapmer Antisense Oligonucleotide as Treatment Candidate for Neurodegenerative Disorders. Pharmaceutics, 14(1), 200.
https://doi.org/10.3390/pharmaceutics14010200
